Publications
5808 Results
- Journal / Conference
- Cancer Survivorship Research Conference (June 18-20, 2014 Atlanta, GA), poster;
- Year
- 2014
- Research Committee(s)
- Cancer Survivorship
Meeting cancer survivors needs: survivors perspective
- Journal / Conference
- Cancer Survivorship Research Conference (June 18-20, 2014 Atlanta, GA), poster;
- Year
- 2014
- Research Committee(s)
- Cancer Survivorship
Results of a survivorship needs assessment survey within a large cooperative group (SWOG)
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 10508);ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral;
- Year
- 2014
- Research Committee(s)
- Sarcoma
- Study Number(s)
- S0033
Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 1016); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
- Year
- 2014
- Research Committee(s)
- Breast
- Study Number(s)
- S0221
Outcome of male patients and black patients enrolled in SWOG S0221, an intergroup chemotherapy study
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr LBA505); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral;
- Year
- 2014
- Research Committee(s)
- Breast
- Study Number(s)
- S0230
Phase III Trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH Analog during Chemotherapy to Reduce Ovarian Failure in Early Stage, Hormone-Receptor Negative Breast Cancer: An International Intergroup Trial of SWOG, IBCSG, ECOG, CALGB (Alliance)
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 558); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session;
- Year
- 2014
- Research Committee(s)
- Breast
- Study Number(s)
- S0307
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery (ClinicalTrials.gov Identifier: NCT00127205)
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 4030);ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S0809
SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA)
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 5006); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session;
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0925
SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab (IMC-A12) versus androgen deprivation alone for patients with new metastatic castration-sensitive prostate cancer
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 5017); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
- Year
- 2014
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0925
Comparison of plasma microRNAs with CTCs and PSA in patients treated on SWOG S0925, a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone for patients with new metastatic hormone-sensitive prostate cancer
- Journal / Conference
- Journal of Clinical Oncology 32:5s (suppl; abstr 9532); ASCO Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session;
- Year
- 2014
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S0927